Abattis Signs Exclusive Distribution Agreement for Proprietary Extraction Technology

Abattis Bioceuticals Corp. (CSE: ATT) (OTCQB: ATTBF) (the "Company" or "Abattis") is pleased to announce it has signed an exclusive distribution agreement effective April 20, 2017 (the "Agreement") with Suzhou Raybot Material Tech Corp. ("Raybot"). The Agreement allows Abattis to use Raybot's proprietary extraction technology and to exclusively sell the extraction equipment and services.

Raybot has developed a proprietary technology which utilizes industrial column chromatography to extract and separate a wide range of materials, in a continuous, closed loop system. This method, which is currently used in the mass production of extracts such as Ginkgo Biloba, Stevia and Ginsenosides among others, has been specifically designed for the extraction of legal cannabis derivatives such as Cannabidiol ("CBD"),Tetrahydrocannabinol ("THC") and Cannabigerol ("CBG") from Marijuana or Hemp. The technology has excellent processing capacity, high extraction yield and significant cost advantages over traditional methods.

The proprietary technology is capable of extracting CBD

e-mail icon Facebook icon Twitter icon LinkedIn icon Reddit icon
Rate this article: